Trial reportCephalalgia : an international journal of headache2022
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Trial report in Cephalalgia : an international journal of headache, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06414044 (STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia), which is not on this map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review.Pain management · 2025Pooled it
- Oral preventive medications for migraine in adults aged 18-65: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Comprehensive preventive treatments for episodic migraine: a systematic review of randomized clinical trials.Frontiers in neurology · 2025Pooled it
- Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults.Frontiers in neurology · 2024Pooled it
- Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.Clinical drug investigation · 2022Pooled it
- Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.Neurology · 2025Trial
- Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.The journal of headache and pain · 2024Trial
- Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.The journal of headache and pain · 2024Trial
- Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort).Neurology and therapy · 2026Article
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.Neurology and therapy · 2026Article
- Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant.Journal of oral & facial pain and headache · 2026Review
- Hallmarks of headache disorders: part 5 - secondary headaches.The journal of headache and pain · 2026Review
- Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results from a Phase 1 Lactation Study.Neurology and therapy · 2025Article
- Gepants: targeting the CGRP pathway for migraine relief.Frontiers in pharmacology · 2025Review
- Population pharmacokinetic modeling of zavegepant, a calcitonin gene-related peptide receptor antagonist, in healthy adults and patients with migraine.CPT: pharmacometrics & systems pharmacology · 2025Article
- Targeting Perineural Invasion in Pancreatic Cancer.Cancers · 2024Review
- Safety and Efficacy of Atogepant for the Preventive Treatment of Migraines in Adults: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Complementary and alternative medicine use in migraine patients: results from a national patient e-survey.Frontiers in neurology · 2024Article
- Atogepant: Mechanism of action, clinical and translational science.Clinical and translational science · 2024Review
- The Polish Experts' Consensus Statement: 2023 update on new therapies for migraine.Archives of medical science : AMS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of migraine.
methodsIn the double-blind, phase 3 ADVANCE trial, participants with 4-14 migraine days/month were randomized to atogepant 10 mg, 30 mg, 60 mg, or placebo once daily for 12 weeks. We evaluated the time course of efficacy of atogepant for the preventive treatment of migraine. Analyses included change from baseline in mean monthly migraine days during each of the three 4-week treatment periods, change in weekly migraine days during weeks 1-4, and proportion of participants with a migraine on each day during the first week.
resultsWe analyzed 873 participants (n = 214 atogepant 10 mg, n = 223 atogepant 30 mg, n = 222 atogepant 60 mg, n = 214 placebo). For weeks 1-4, mean change from baseline in mean monthly migraine days ranged from -3.1 to -3.9 across atogepant doses vs -1.6 for placebo (
conclusionAtogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.